Alzheimer's & Dementia: The Journal of the Alzheimer's Association
Volume 3, Issue 4 , Pages 266-282 , October 2007

Mild cognitive impairment and cognitive impairment, no dementia: Part A, concept and diagnosis

  • Howard Chertkow

      Affiliations

    • Bloomfield Centre for Research in Aging, Lady Davis Institute for Medical Research, Sir Mortimer B. Davis-Jewish General Hospital, McGill University, Montreal, Quebec, Canada
    • Division of Geriatric Medicine, Department of Medicine, Sir Mortimer B. Davis-Jewish General Hospital, McGill University, Montreal, Quebec, Canada
    • Department of Neurology and Neurosurgery, McGill University, Montreal, Quebec, Canada
    • Centre de recherche, Institut Universitaire de Gériatrie de Montréal, Montreal, Quebec, Canada
    • Corresponding Author InformationCorresponding author. Tel.: (514) 340-8260; Fax: (514) 340-8295.
    • ,
  • Ziad Nasreddine

      Affiliations

    • Département de médecine, service de neurologie, Hôpital Charles LeMoyne and Université de Sherbrooke, Montreal, Quebec, Canada
    • ,
  • Yves Joanette

      Affiliations

    • Centre de recherche, Institut Universitaire de Gériatrie de Montréal, Montreal, Quebec, Canada
    • Faculté de Médicine, Université de Montréal, Montréal, Quebec, Canada
    • ,
  • Valérie Drolet

      Affiliations

    • Centre de recherche, Institut Universitaire de Gériatrie de Montréal, Montreal, Quebec, Canada
    • ,
  • John Kirk

      Affiliations

    • Division of Geriatric Medicine, Department of Medicine, Sir Mortimer B. Davis-Jewish General Hospital, McGill University, Montreal, Quebec, Canada
    • ,
  • Fadi Massoud

      Affiliations

    • Service de Gériatrie, Centre Hospitalier de l’Université de Montréal, and Département de Médecine, Université de Montréal, Montréal, Quebec, Canada
    • ,
  • Sylvie Belleville

      Affiliations

    • Centre de recherche, Institut Universitaire de Gériatrie de Montréal, Montreal, Quebec, Canada
    • Department de Psychologie, Université de Montréal, Montréal, Quebec, Canada
    • ,
  • Howard Bergman

      Affiliations

    • Bloomfield Centre for Research in Aging, Lady Davis Institute for Medical Research, Sir Mortimer B. Davis-Jewish General Hospital, McGill University, Montreal, Quebec, Canada
    • Division of Geriatric Medicine, Department of Medicine, Sir Mortimer B. Davis-Jewish General Hospital, McGill University, Montreal, Quebec, Canada

References 

  1. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary?. Control Clin Trials. 1996;17:1–12
  2. Woolf SH, Battista RN, Anerson G, Logan A, Wang E. Asssessing the clinical effectiveness of preventive manoeuvers: analytical principles and systematic methods in reviewing evidence and developing clinical practice recommendations. J Clin Epidemiol. 1990;43:891–905
  3. CSHA. The incidence of dementia in Canada: the Canadian Study of Health and Aging Working Group. Neurology. 2000;55:66–73
  4. Drachman D. If we live long enough, will we all be demented?. Neurology. 1994;44:1563–1565
  5. McKann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA work group under the auspices of the Department of Health Services Task Force on Alzheimer’s disease. Neurology. 1984;34:939–944
  6. Crook T, Bartus RT, Ferris SH, Whitehouse P, Cohen GD, Gershon SG. Age-associated memory impairment: proposed diagnostic criteria and measures of clinical change: report of a National Institute of Mental Helath Work Group. Dev Neuropsychol. 1986;2:261–276
  7. Blackford RC, LaRue A. Criteria for diagnosing age-associated memory impairment: proposed revisions from the field. Dev Neuropsychol. 1989;5:295–306
  8. Hanninen T, Hallikainen M, Koivisto K, Helkala EL, Reinikainen KJ, Soininen H, et al. A follow-up study of age-associated memory impairment: neuropsychological predictors of dementia. J Am Geriatr Soc. 1995;43:1007–1015
  9. Larrabee GJ. Age-associated memory impairment: definition and psychometric characteristics. Aging Neuropsychology & Cognition. 1996;3:118–131
  10. Salthouse TA. Theoretical perspectives on cognitive aging. In: Hillsdale, NJ: Lawrence Erlbaum Associates, Inc; 1991;p. 438
  11. Collie A, Maruff P, Shafiq-Antonacci R, Smith M, Hallup M, Schofield PR, et al. Memory decline in healthy older people: implications for identifying mild cognitive impairment. Neurology. 2001;56:1533–1538
  12. Sliwinski M, Lipton RB, Buschke H, Stewart W. The effects of preclinical dementia on estimates of normal cognitive functioning in aging. J Gerontol B Psychol Sci Soc Sci. 1996;51:217–225
  13. Bennett DA, Schneider JA, Arvanitakis Z, Kelly JF, Aggarwal NF, Shah RC, et al. Neuropathology of older persons without cognitive impairment from two community-based studies. Neurology. 2006;66:1837–1844
  14. Tuokko H, Frerichs RJ. Cognitive impairment with no dementia (CIND): longitudinal studies, the findings and the issues. Clin Neuropsychol. 2000;14:504–525
  15. Graham JE, Rockwood K, Beattie BL, Eastwood R, Gauthier S, Tuokko H, et al. Prevalence and severity of cognitive impairment with and without dementia in an elderly population. Lancet. 1997;349:1793–1796
  16. Ebly EM, Hogan DB, Parhad IM. Cognitive impairment in the nondemented elderly: results from the Canadian Study of Health and Aging. Arch Neurol. 1995;52:612–619
  17. Tuokko H, Frerichs R, Graham J, Rockwood K, Kristjansson B, Fisk J, et al. Five-year follow-up of cognitive impairment with no dementia. Arch Neurol. 2003;60:577–582
  18. Feldman H, Levy AR, Hsiung GY, Peters KR, Donald A, Black SE, et al. A Canadian cohort study of cognitive impairment and related dementias (ACCORD): study methods and baseline results. Neuroepidemiology. 2003;22:265–274
  19. Palmer K, Wang H-X, Backman L, Winblad B, Fratiglioni L. Differential evolution in non-demented older persons: results from the Kungsholmen Project. Am J.Psychiatry. 2002;159:436–442
  20. Folstein M, Anthony JC, Parhad I, Duffy B, Gruenberg EM. The meaning of cognitive impairment in the elderly. J Am Geriatr Soc. 1985;33:228–235
  21. Hughes C, Berg L, Danziger W, Coben L, Martin R. A new clinical scale for the staging of dementia. Br J Psychiatry. 1982;140:566–572
  22. Morris JC, McKeel DW, Storandt M, Rubin EH, Price JL, Grant EA, et al. Very mild Alzheimer’s disease: informant-based clinical, psychometric, and pathologic distinction from normal aging. Neurology. 1991;41:469–478
  23. Reisberg B, Ferris SH, de Leon MJ, Crook T. Global Deterioration Scale (GDS). Psychopharmacol Bull. 1988;24:661–663
  24. Kluger A, Ferris SH, Golomb J, Mittelman MS, Reisberg B. Neuropsychological prediction of decline to dementia in nondemented elderly. J Geriatr Psychiatry Neurol. 1999;12:168–179
  25. Jonker C, Geerlings MI, Schmand B. Are memory complaints predictive for dementia? a review of clinical and population-based studies. Int J Geriatr Psychiatry. 2000;15:983–991
  26. O’Brien J, Beats B, Hill K, Howard R, Sahakian B, Levy R. Do subjective memory complaints precede dementia? a three-year follow-up of patients with supposed “benign senescent forgetfulness”. Int J Geriatr Psychiatry. 1992;7:481–486
  27. Flicker C, Ferris SH, Reisberg B. A longitudinal study of cognitive function in elderly persons with subjective memory complaints. J Am Geriatr Soc. 1993;41:1029–1032
  28. Levy R. Report of the working party of the International Psychogeriatric Association in collaboratino with the World Health Organization: aging-associated cognitive decline [published erratum appears in Int Psychogeriatr 1994;6:133]. Int Psychogeriatr. 1994;6:63–68
  29. Smith AD, Jobst K. Use of structural imaging to study the progression of Alzheimer’s disease. Br Med Bull. 1996;52:3
  30. Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E. Mild cognitive impairment: clinical characterization and outcome. Arch Neurol. 1999;56:303–308
  31. Petersen RC, Stevens JC, Ganguli M, Tangalos EG, Cummings JL, DeKosky ST. Practice parameter: early detection of dementia: mild cognitive impairment (an evidence-based review)—report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2001;56:1133–1142
  32. Petersen RC, Smith GE, Ivnik RJ, Tangalos EG, Schaid DJ, Thibodeau SN, et al. Apolipoprotein E status as a predictor of the development of Alzheimer’s disease in memory-impaired individuals [published erratum appears in JAMA 1995;274:538]. JAMA. 1995;273:1274–1278
  33. Petersen RC. Mild cognitive impairment as a diagnostic entity. J Intern Med. 2004;256:183–194
  34. Ganguli M, Dodge HH, Shen C, DeKosky ST. Mild cognitive impairment, amnestic type: an epidemiologic study. Neurology. 2004;63:115–121
  35. Lopez O, Jagust W, DeKosky S, Becker J. Risk factors for mild cognitive impairment in a population study. Neurology. 2002;58:A238
  36. Chertkow H. Mild memory loss in the elderly: can we predict development in dementia?. Can J Neurol Sci. 1998;25:1;S4
  37. Royall DR, Chiodo LK, Polk MJ. Misclassification is likely in the assessment of mild cognitive impairment. Neuroepidemiology. 2004;23:185–191
  38. Winblad B, Palmer K, Kivipelto M, Jelic V, Fratiglioni L, Wahlund LO, et al. Mild cognitive impairment: beyond controversies, towards a consensus—report of the International Working Group on Mild Cognitive Impairment. J Intern Med. 2004;256:240–246
  39. Chertkow H. What are the characteristics of patients with mild cognitive impairment who do not progress to dementia?. The American Neurological Association, San Francisco, CA, Oct 21 2003;
  40. Chertkow HM, Duong A, Philips N, Bergman H, Babins L, Kelner N. Mild cognitive impairment (the danger of basing the diagnosis on published normative groups (P3-072)). Paper presented at ICAD-Alzheimer’s Association 10th International Conference on Alzheimer’s Disease and Related Disorders 2006;Madrid, Spain
  41. Portet F, Ousset PJ, Visser PJ, Frisoni GB, Nobili F, Scheltens P, et al. Mild cognitive impairment (MCI) in medical practice: a critical review of the concept and new diagnostic procedure—report of the MCI Working Group of the European Consortium on Alzheimer’s Disease. J Neurol Neurosurg Psychiatry. 2006;77:714–718
  42. Grundman M, Petersen RC, Morris JC. ADSC Cooperative Study: rate of dementia of the Alzheimer type (DAT) in subjects with mild cognitive impairment. Neurology. 1996;46:A403
  43. Visser PJ, Kester A, Jolles J, Verhey F. Ten-year risk of dementia in subjects with mild cognitive impairment. Neurology. 2006;67:1201–1207
  44. Chertkow H, Verret L, Bergman H, Wolfson C, McKelvey R. Predicting progression to dementia in elderly subjects with mild cognitive impairment (a multidisciplinary approach). Paper presented at 2001 Contemporary Clinical Issues Plenary Session, 53rd Annual Meeting American Academy of Neurology 2001;Philadelphia, PA
  45. Ritchie K, Leibovici D, Ledesert B, Touchon J. A typology of sub-clinical senescent cognitive disorder. B J Psychiatry. 1996;168:470–476
  46. Morris JC, Storandt M, Miller JP, McKeel DW, Price JL, Rubin EH, et al. Mild cognitive impairment represents early-stage Alzheimer disease. Arch Neurol. 2001;58:397–405
  47. Luis CA, Loewenstein DA, Acevedo A, Barker WW, Duara R. Mild cognitive impairment: directions for future research. Neurology. 2003;61:438–444
  48. Loewenstein DA, Barker WW, Harwood DG, Luis C, Acevedo A, Rodriguez I, et al. Utility of a modified Mini-Mental State Examination with extended delayed recall in screening for mild cognitive impairment and dementia among community dwelling elders. Int J Geriatr Psychiatry. 2000;15:434–440
  49. Ritchie K, Artero S, Touchon J. Classification criteria for mild cognitive impairment: a population-based validation study. Neurology. 2001;56:37–42
  50. Ritchie K, Touchon J. Mild cognitive impairment: conceptual basis and current nosological status. Lancet. 2000;355:225–228
  51. Chertkow HM, Bergman H, Wolfson C, Babins L, Kelner N. Standard neuropsychological tests do not predict development of Alzheimer’s Disease in indivduals with “Age-associated Cognitive Decline”. Can J Neurol Sci. 1998;25(Suppl 1):S27
  52. Craik F. Memory changes in normal aging. Curr Dir Psychol Sci. 1994;3:1558
  53. Artero S, Touchon J, Ritchie K. Disability and mild cognitive impairment: a longitudinal population-based study. Int J Geriatr Psychiatry. 2001;16:1092–1097
  54. Visser P, Verhey F. Distinction between preclinical Alzheimer’s disease and depression. J Am Geriatr Soc. 2000;48:479–484
  55. Lautenschlager NT, Riemenschneider M, Drzezga A, Kurz AF. Primary degenerative mild cognitive impairment: study population, clinical, brain imaging and biochemical findings. Dement Geriatr Cogn Disord. 2001;12:379–386
  56. Bouras C. Evolution of AD pathology in the aging brain. Paper presented at American Academy of Neurology 2002;Geneva, Switzerland
  57. Markesbery W, Schmitt FA, Kryscio RH, Davis D, Smith CD, Wekstein D. Neuropatholic substrate of mild cognitive impairment. Arch Neurol. 2006;63:38–46
  58. Knopman DS, Parisi JE, Salviati A, Floriach-Robert M, Boeve BF, Ivnik RJ, et al. Neuropathology of cognitively normal elderly. J Neuropathol Exp Neurol. 2003;62:1087–1095
  59. Bennett DA, Schneider JA, Bienias JL, Evans DA, Wilson RS. Mild cognitive impairment is related to Alzheimer disease pathology and cerebral infarctions. Neurology. 2005;64:83441
  60. Davis KL, Mohs RC, Marin D, Purohit DP, Perl DP, Lantz M, et al. Cholinergic markers in elderly patients with early signs of Alzheimer disease. JAMA. 1999;281:1401–1406
  61. DeKosky ST, Ikonomovic M, Cochran EJ, Kordower JH, Mufson EJ. Cholinergic upregulation in hippocampus in mild cognitive impairment (relation to Alzheimer Neuropathology). Paper presented at 54th Annual Meeting of the American Academy of Neurology, Denver, Colorado, April 13-20 2002;
  62. Daly E, Zaitchik D, Copeland M, Schmahmann J, Gunther J, Albert M. Predicting conversion to Alzheimer disease using standardized clinical information. Arch Neurol. 2000;57:675–680
  63. Fisk JD, Merry HR, Rockwood K. Variations in case definition affect prevalence but not outcomes of mild cognitive impairment. Neurology. 2003;61:1179–1184
  64. Hsiung G-Y, Johnston D, Donald A, Feldman H. An analysis of vascular risk factors and ApoE genotype in subtypes of dementia in the ACCORD study. Neurology. 2002;58(Suppl 3):A107
  65. Jonker C, Schmand B, Lindeboom J, Havekes LM, Launer LJ. Association between apolipoprotein E epsilon4 and the rate of cognitive decline in community-dwelling elderly individuals with and without dementia. Arch Neurol. 1998;55:1065–1069
  66. Dik MG, Jonker C, Bouter LM, Geerlings MI, van Kamp GJ, Deeg DJ. APOE-epsilon4 is associated with memory decline in cognitively impaired elderly. Neurology. 2000;54:1492–1497
  67. Small BJ, Basun H, Backman L. Three-year changes in cognitive performance as a function of apolipoprotein E genotype: evidence from very old adults without dementia. Psychology & Aging. 1998;13:80–87
  68. Lehmann M, Gottfries CG, Regland B. Identification of cognitive impairment in the elderly: homocysteine is an early marker. Dement Geriatr Cogn Disord. 1999;10:12–20
  69. Corrada M, Kawas C. Plasma total cholesterol, LDL, HDL levels and the risk of Alzheimer disease: the Baltimore Longitudinal Study of Aging. Neurology. 2002;58:A106
  70. Yaffe K, Simonsick E, Launer L, Lindquist K, Penninx BW, Pahor M, et al. Inflammatory markers and cognitive decline in well-functioning elders: the Health ABC Study. Neurology. 2002;58:A106
  71. Jack CR, Petersen RC, Xu Y, O’Brien PC, Smith GE, Ivnik RJ, et al. Rate of medial temporal lobe atrophy in typical aging and Alzheimers disease. Neurology. 1998;51:993–999
  72. Fox NC. Increased rates of atrophy in early and preclinical AD: studies with registration of serial MRI. Neurobiol Aging. 2000;21:S74
  73. Jack CR, Petersen RC, Xu Y, O’Brien PC, Smith GE, Ivnik RJ, et al. Rates of hippocampal atrophy correlate with change in clinical status in aging and AD. Neurology. 2000;55:484–489
  74. de Leon MJ, Convit A. Longitudinal measures of hippocampal formation pathology and CSF measures of phospho-tau and amyloid beta: early markers for Alzheimer disease. Paper presented at Seventh International Geneva/Springfield symposium on advances in Alzheimer Therapy 2002;Geneva, Switzerland
  75. de Leon MJ, Convit A, Wolf OT, Tarshish CY, DeSanti S, Rusinek H, et al. Prediction of cognitive decline in normal elderly subjects with 2-[(18)F]fluoro-2-deoxy-D-glucose/poitron-emission tomography (FDG/PET). Proc Natl Acad Sci U S A. 2001;98:10966–10971
  76. Reiman EM, Caselli RJ, Yun LS, Chen K, Bandy D, Minoshima S, et al. Preclinical evidence of Alzheimer’s disease in persons homozygous for the epsilon 4 allele for apolipoprotein E. N Engl J Med. 1996;334:752–758
  77. McKelvey R, Bergman H, Stern J, Rush C, Zahirney G, Chertkow H. Lack of prognostic significance of SPECT abnormalities in non-demented elderly subjects with memory loss. Can J Neurol Sci. 1999;26:23–28
  78. Johnson KA, Jones K, Holman BL, Becker JA, Spiers PA, Satlin A, et al. Preclinical prediction of Alzheimer’s disease using SPECT. Neurology. 1998;50:1563–1571
  79. Kantarci K, Jack CR, Xu YC, Campeau NJ, O’Brien PC, Smith GE, et al. Regional metabolic patterns in mild cognitive impairment and Alzheimer’s disease: a 1H MRS study. Neurology. 2000;55:210–217
  80. Nordberg A. PET activation in MCI and AD patients. Paper presented at Seventh Annual Springfield/Geneva symposium on advances in Alzheimer Therapy 2002;Geneva, Switzerland
  81. Bookheimer SY, Strojwas M, Cohen MS, Saunders AM, Pericak-Vance MA, Mazziotta JC, et al. Patterns of brain activation in people at risk for Alzheimer’s disease. N Engl J Med. 2000;343:450–456
  82. Backman L. The cognitive transition from normal aging to AD. Paper presented at the Seventh Springfield/Geneva symposium on advances in Alzheimer Therapy 2002;Geneva, Switzerland
  83. Bozoki A, Giordani B, Heidebrink J, Berent S, Foster N. Mild cognitive impairments predict dementia in non-demented elderly patients with memory loss. Arch Neurol. 2001;58:411–416
  84. Tierney MC, Szalai JP, Snow WG, Fisher RH. The prediction of Alzheimer disease: the role of patient and informant perceptions of cognitive deficits. Arch Neurol. 1996;53:423–427
  85. Devanand DP, Folz M, Gorlyn M, Moeller JR, Stern Y. Questionable dementia: clinical course and predictors of outcome. J Am Geriatr Soc. 1997;45:321–328
  86. Devanand DP, Michaels-Marston KS, Liu X, Pelton GH, Padilla M, Marder K, et al. Olfactory deficits in patients with mild cognitive impairment predict Alzheimer’s disease at follow-up. Am J Psychiatry. 2000;157:1399–1405
  87. Albert MS, Moss MB, Tanzi R, Jones K. Preclinical prediction of AD using neuropsychological tests. J Int Neuropsychol Soc. 2001;7:631–639
  88. Graves AB, Bowen JD, Rajaram L, McCormick WC, McCurry SM, Schellenberg GD, et al. Impaired olfaction as a marker for cognitive decline: interaction with apolipoprotein E epsilon4 status. Neurology. 1999;53:1480–1487
  89. Schipper HM, Chertkow H, Mehindate K, Frankel D, Melmed C, Bergman H. Evaluation of heme oxygenase-1 as a systemic biological marker of sporadic AD. Neurology. 2000;54:1297–1304
  90. Andreasen N, Minthon L, Vanmechelen E, Vanderstichele H, Davidsson P, Winblad P, et al. Cerebrospinal fluid tau and Abeta42 as predictors of development of Alzheimer’s disease in patients with mild cognitive impairment. Neurosci Lett. 1999;273:5–8
  91. Saxton J, Lopex O, Ratcliff G, Dulberg C, Fried L, Carlson MC, et al. Preclinical Alzheimer disease: neuropsychological test performance 1.5 to 8 years prior to onset. Neurology. 2004;63:2341–2347
  92. Frisoni GB, Padovani A, Wahlund LO. The predementia diagnosis of Alzheimer disease. Alzheimer Dis Assoc Disord. 2004;18:51–53
  93. Bennett DA. Mild cognitive impairment. Clin Geriatr Med. 2004;20:15–25
  94. Bennett DA, Wilson RS, Schneider JA, Evans DA, Beckett LA, Aggarwal NT, et al. Natural history of mild cognitive impairment in older persons. Neurology. 2002;59:198–205
  95. Dubois B, Albert ML. Amnestic MCI or prodromal Alzheimer’s disease?. Lancet Neurol. 2004;3:246–248
  96. Morris J. Mild cognitive impairment is early-stage Alzheimer disease. Arch Neurol. 2006;63:15–16
  97. Bennett DA. Update on mild cognitive impairment. Curr Neurol Neurosci Rep. 2003;3:379–384
  98. Ritchie K. Mild cognitive impairment: an epidemiological perspective. Dialogues in Clinical Neuroscience. 2004;6:401–408
  99. Larrieu S, Letenneur L, Orgogozo JM, Fabrigoule C, Amieva H, Le Carret N, et al. Incidence and outcome of mild cognitive impairment in a population-based prospective cohort. Neurology. 2002;59:1594–1599
  100. Wolf H, Grunwald M, Ecke GM, Zedlick D, Bettin S, Dannenberg C, et al. The prognosis of mild cognitive impairment in the elderly. J Neural Transm Suppl. 1998;54:31–50
  101. Chertkow H. Five year follow-up of mild cognitive impairment. predictors of progression—the 8th International Conference on Alzheimer’s Disease and Related Disorders. Stockholm, Sweden, July 2002;
  102. Davis HS, Rockwood K. Conceptualization of mild cognitive impairment: a review. Int J Geriatr Psychiatry. 2004;19:313–319
  103. Petersen RC, Ivnik RJ, Tangalos EG, Kokmen E. Mild cognitive impairment: clinical characterization and outcome—correction. Arch Neurol. 1999;56:6
  104. Collie A, Maruff P. An analysis of systems of classifying mild cognitive impairment in older people. Aust N Z J Psychiatry. 2002;36:133–140
  105. Feldman HH, Jacova C. Mild cognitive impairment. Am J Geriatr Psychiatry. 2005;13:645–655
  106. DeCarli C. Mild cognitive impairment: prevalence, prognosis, aetiology, and treatment. Lancet Neurol. 2003;2:15–21
  107. Salloway S, Ferris S, Kluger A, Goldman R, Griesing T, Kumar D, et al. Efficacy of donepezil in mild cognitive impairment: a randomized placebo-controlled trial. Neurology. 2004;63:651–657
  108. Petersen RC, Doody R, Kurz A, Mohs RC, Morris JC, Rabins RV, et al. Current concepts in mild cognitive impairment. Arch Neurol. 2001;58:1985–1992
  109. Jelic V, Winblad B. Treatment of mild cognitive impairment: rationale, present and future strategies. Acta Neurol Scand Suppl. 2003;179:83–93
  110. Kalbe E, Kessler J, Calabrese P, Smith R, Passmore AP, Brand M, et al. DemTect: a new, sensitive cognitive screening test to support the diagnosis of mild cognitive impairment and early dementia. Int J Geriatr Psychiatry. 2004;19:136–143
  111. Ivanoiu A, Adam S, Van der Linden M, Salmon E, Juillerat AC, Mulligan R, et al. Memory evaluation with a new cued recall test in patients with mild cognitive impairment and Alzheimer’s disease. J Neurol. 2005;252:47–55
  112. Nasreddine ZS, Phillips NA, Bedirian V, Charbonneau S, Whitehead V, Collin V, et al. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc. 2005;53:695–699
  113. Yamamoto S, Mogi N, Umegaki H, Suzuki H, Ando F, Shimokata H, et al. The clock drawing test as a valid screening method for mild cognitive impairment. Dement Geriatr Cogn Disord. 2004;18:172–179
  114. Molloy DW. Screening for mild cognitive impairment: comparing the SMMSE and the ABCS. Can J Psychiatry. 2005;50:52–58
  115. Xu G, Meyer JS, Huang Y, Chen G, Chowdhury M, Quach M. Cross-cultural comparison of mild cognitive impairment between China and USA. Curr Alzheimer Res. 2004;1:55–61
  116. Artero S, Ritchie K. The detection of mild cognitive impairment in the general practice setting. Aging Ment Health. 2003;7:251–258
  117. Tang-Wai DF, Knopman DS, Geda YE, Edland SD, Smith GE, Ivnik RJ, et al. Comparison of the short test of mental status and the mini-mental state examination in mild cognitive impairment. Arch Neurol. 2003;60:1777–1781
  118. Shankle WR, Romney AK, Hara J, Fortier D, Dick MB, Chen JM, et al. Methods to improve the detection of mild cognitive impairment. Proc Natl Acad Sci U S A. 2005;102:4919–4924
  119. Borson S, Scanlan JM, Watanabe J, Tu SP, Lessig M. Simplifying detection of cognitive impairment: comparison of the Mini-Cog and Mini-Mental State Examination in a multiethnic sample. J Am Geriatr Soc. 2005;53:871–874
  120. Callahan CM, Unverzagt FW, Hui SL, Perkins AJ, Hendrie HC. Six-item screener to identify cognitive impairment among potential subjects for clinical research. Med Care. 2002;40:771–781
  121. Canning SJ, Leach L, Stuss D, Ngo L, Black SE. Diagnostic utility of abbreviated fluency measures in Alzheimer disease and vascular dementia. Neurology. 2004;62:556–562
  122. Darby D, Maruff P, Collie A, McStephen M. Mild cognitive impairment can be detected by multiple assessments in a single day. Neurology. 2002;59:1042–1046Oct 8
  123. Hanninen T, Hallikainen M, Tuomainen S, Vanhanen M, Soininen H. Prevalence of mild cognitive impairment: a population-based study in elderly subjects. Acta Neurol Scand. 2002;106:148–154
  124. Kabani NJ, Sled JG, Chertkow H. Magnetization transfer ratio in mild cognitive impairment and dementia of Alzheimer’s type. Neuroimage. 2002;15:604–610
  125. Busse A, Bischkopf J, Riedel-Heller SG, Angermeyer MC. Subclassifications for mild cognitive impairment: prevalence and predictive validity. Psychol Med. 2003;33:1029–1038
  126. Lambon Ralph MA, Patterson K, Graham N, Dawson K, Hodges JR. Homogeneity and heterogeneity in mild cognitive impairment and Alzheimer’s disease: a cross-sectional and longitudinal study of 55 cases. Brain. 2003;126:2350–2362
  127. Lopez OL, Jagust WJ, DeKosky ST, Becker JT, Fitzpatrick A, Dulberg C, et al. Prevalence and classification of mild cognitive impairment in the Cardiovascular Health Study Cognition Study: part 1. Arch Neurol. 2003;60:1385–1389
  128. Farlow MR, He Y, Tekin S, Xu J, Lane R, Charles HC. Impact of APOE in mild cognitive impairment. Neurology. 2004;63(10):1898–1901Nov 23
  129. Feldman H, Scheltens P, Scarpini E, Hermann N, Mesenbrink P, Mancione L, et al. Behavioral symptoms in mild cognitive impairment. Neurology. 2004;62:1199–1201
  130. Grundman M, Petersen RC, Ferris SH, Thomas RG, Aisen PS, Bennett DA, et al. Mild cognitive impairment can be distinguished from Alzheimer disease and normal aging for clinical trials. Arch Neurol. 2004;61:59–66
  131. Solfrizzi V, Panza F, Colacicco AM, D’Introno A, Capurso C, Torres F, et al. Vascular risk factors, incidence of MCI, and rates of progression to dementia. Neurology. 2004;63:1882–1891
  132. de Jager CA, Budge MM. Stability and predictability of the classification of mild cognitive impairment as assessed by episodic memory test performance over time. Neurocase. 2005;11:72–79
  133. Devanand DP, Pelton GH, Zamora D, Liu X, Tabert MH, Goodkind M, et al. Predictive utility of apolipoprotein E genotype for Alzheimer disease in outpatients with mild cognitive impairment. Arch Neurol. 2005;62:975–980
  134. Geslani DM, Tierney MC, Herrmann N, Szalai JP. Mild cognitive impairment: an operational definition and its conversion rate to Alzheimer’s disease. Dement Geriatr Cogn Disord. 2005;19(5-6):383–389
  135. Kumar R, Dear KB, Christensen H, Ilschner S, Jorm AF, Meslin C, et al. Prevalence of mild cognitive impairment in 60- to 64-year-old community-dwelling individuals: The Personality and Total Health through Life 60+ Study. Dement Geriatr Cogn Disord. 2005;19:67–74
  136. Purser JL, Fillenbaum GG, Pieper CF, Wallace RB. Mild cognitive impairment and 10-year trajectories of disability in the Iowa Established Populations for Epidemiologic Studies of the Elderly cohort. J Am Geriatr So. 2005;53:1966–1972
  137. Visser PJ, Scheltens P, Verhey FR. Do MCI criteria in drug trials accurately identify subjects with predementia Alzheimer’s disease?. J Neurol Neurosurg Psychiatry. 2005;76:1348–1354
  138. Verghese J, Levalley A, Derby C, Kuslansky G, Katz M, Hall C, et al. Leisure activities and the risk of amnestic mild cognitive impairment in the elderly. Neurology. 2006;66:821

PII: S1552-5260(07)00562-6

doi: 10.1016/j.jalz.2007.07.013

Alzheimer's & Dementia: The Journal of the Alzheimer's Association
Volume 3, Issue 4 , Pages 266-282 , October 2007

Article Tools